Guided by advances in genomics and proteomics, IngenoVax has developed a novel, fully-synthetic cancer vaccine platform ("Microbial Mimetics") for the immunotherapy of a wide range of solid tumor types, further rendering them susceptible to immune checkpoint inhibitor therapy. With proof of concept studies completed and IP issued, we are performing IND-enablement studies for our lead candidate.
Company Details
- Address
- 1, Boulder,co 80309,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ingenovax.com
- HQ
- Boulder, CO
Ingenovax Questions
Ingenovax's website is ingenovax.com
Ingenovax's LinkedIn profile is https://www.linkedin.com/company/ingenobio
Ingenovax's industry is
Biotechnology Research
Ingenovax's categories are Biotechnology Research
